NCT05546268: Study of Oral MRT-2359 in Selected Cancer Patients

Sponsor: Monte Rosa Therapeutics, Inc. Phase: PHASE1. Conditions: NSCLC, SCLC, High Grade Neuroendocrine Cancer, DLBCL, L-MYC and N-MYC Amplified Solid Tumors, NSCLC With High or Low L-MYC or N-MYC Expression, HR-positive, HER2-negative Breast Cancer, Prostate Cancer